With the American Association for Cancer Research’s annual conference now underway, oncology researchers can expect ...

The targeted drug release device TAR-200 shows promising response and disease-free survival rates in specific populations of ...

The FDA is currently reviewing Merck’s sBLA for Keytruda in head and neck cancer, with a target action date of June 23.

With ivonescimab’s data coming solely from China, its prospects in the U.S., where Summit owns the rights, remain up in the ...

DELFI Diagnostics has clinically validated FirstLook Lung, its blood test designed to improve early detection of lung cancer, ...

While AbbVie handily beat expectations this quarter, the company faces declining Humira sales and a challenged aesthetics business, plus the same macro headwinds blowing against the entire industry.

As tariffs, HHS workforce cuts and the ouster of CBER Director Peter Marks threaten the “lifeblood” of the cell and gene ...